D STATES PATENT AND TRADEMA

Applicant:

Fodstad et al

Serial No .:

08/403,844

April 18, 19

Filed:

Notice of Allow. Date:

June 27, 2000

Examiner:

Batch No .:

Gailene R. Gabel

Group Art Unit:

1641

Docket:

7885.33USF1

Due Date: Title:

IMPROVED METHOD FOR DETECTION OF SPECIFIC TARGET CELLS IN SPECIALIZED

OR MIXED CELL POPULATION AND SOLUTIONS CONTAINING MIXED CELL

POPULATIONS

CERTIFICATE UNDER 37 CFR 1.8: The undersigned hereby certifies that this Transmittal Letter and the paper, as described herein, are being deposited in the United States Postal Service, as first class mail, with sufficient postage, in an envelope addressed to: BOX AF Assistant Commissioner for Patents, Washington, D.C. 20231, on June 27.

Peter Rauka

Name. John J. Gresens

Reg. No.: 33,112 JJG/KMC/pjr

BOX AF

Assistant Commissioner for Patents

Washington, D.C. 20231

We are transmitting herewith the attached:

Transmittal Sheet in duplicate containing Certificate of Mailing


Amendment

Return postcard

Please consider this a PETITION FOR EXTENSION OF TIME for a sufficient number of months to enter these papers, if appropriate. Please charge any additional fees or credit overpayment to Deposit Account No. 13-2725. A duplicate of this sheet is enclosed.

MERCHANT & GOULD P.C. P.O. Box 2903, Minneapolis, MN 55402-0903 (612) 332-5300

(PTO TRANSMITTAL - GENERAL)



RESPONSE UNDER 37 C.F.R. 1.116 EXPEDITED PROCEDURE EXAMINING GROUP 1641

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant:

Fodstad et al.

Examiner:

Gailene R. Gabel

Serial No.:

08/403,844

Group Art Unit:

1641

Filed:

April 18, 1995

Docket No.:

7885.33USF1

Title:

IMPROVED METHOD FOR DETECTION OF SPECIFIC TARGET

CELLS IN SPECIALIZED OR MIXED CELL POPULATION AND

SOLUTIONS CONTAINING MIXED CELL POPULATIONS

CERTIFICATE UNDER 37 CFR 1.8:

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail, with sufficient postage, in an envelope addressed to: Assistant Commissioner for Patents, Washington, D.C. 20231 on June 27,

/

AMENDMENT UNDER 37 C.F.R. § 1.116

BOX AF Assistant Commissioner for Patents Washington, D.C. 20231

Dear Sir:

IN THE CLAIMS

Please amend the claims as follows.

39. (Amended) The method of claim 22, wherein the monoclonal antibody or antibody fragment is directed against fibronectin receptor, β-integrin, vitronectin receptor, αγβ3-integrin, P-seletin, GMP-140, CD44-variants, N-CAM, E-cadherin, Le^γ, CEA, EGF receptor, cerbB-2, HER2, transferin receptor, TNF-receptor, high molecular weight antigen [(HMW 250,000)], p95-100, TP-1 and TP-3 epitope, Mv 200kD, Mv160kD, MOC-31 epitope, cluster 2 epithelial antigen, MUC-1 antigen, DF3-epitope, gp290kD, prostate high molecular antigen

Mas